Ophidion

Ophidion is a biotechnology company that delivers a central nervous system therapeutics to targeted sites in the brain. The company uses a Trojan horse strategy to exploit an endogenous receptor-mediated transport system to deliver small molecule drugs and biologics into the brain. They are currently focused on developing a pipeline to deliver gene-silencing therapies to treat neurodegenerative diseases, including diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease) as well as Huntington’s disease.

Ophidion platform technology is amenable to delivering multiple classes of drugs, including small molecules and macromolecules (gene therapeutics, siRNA’s, antibodies, peptides, and other macromolecules). It also has an advanced program that is positioned to start pivotal clinical trials to treat anxiety-related disorders, together with a patented companion biomarker diagnostic to select the appropriate patient population.

Ophidion headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $40.8M in funding across 24 round(s). With a team of 1-10 employees, Ophidion is actively contributing to advancements in Biotechnology. Their latest funding round, Convertible Note - Ophidion, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.